This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Array Biopharma Inc.. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014
Title: Scott Alan Pratt: Innovator in Pharmaceutical Modulation
Introduction
Scott Alan Pratt is a notable inventor based in Longmont, Colorado. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that modulate GPR119, a receptor involved in metabolic processes.
Latest Patents
Scott holds a patent for "Piperidinyl-substituted lactams as GPR119 modulators." This patent describes compounds that are useful in treating or preventing various diseases, including type 2 diabetes, diabetic complications, metabolic syndrome, obesity, dyslipidemia, and related conditions. His innovative work in this area has the potential to impact many lives positively.
Career Highlights
Scott is currently associated with Array Biopharma Inc., where he continues to advance his research and development efforts. His expertise in pharmaceutical modulation has positioned him as a valuable asset in the industry.
Collaborations
Throughout his career, Scott has collaborated with talented individuals such as David A. Mareska and Thomas Daniel Aicher. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.
Conclusion
Scott Alan Pratt's contributions to pharmaceutical science, particularly through his patent on GPR119 modulators, highlight his role as an influential inventor. His work continues to pave the way for advancements in the treatment of metabolic diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile